Bone Metastases - Pipeline Insight, 2024

This “Bone Metastases - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bone Metastases Understanding

Bone Metastases: Overview

Bone metastasis occurs when cancer cells from other parts of the body spread to the bone. The most common area for bone metastasis is the spine. The first symptom a person might experience is bone pain. The most common symptom of bone metastasis is pain. Other symptoms are bone fractures, spinal cord compression and anemia. Bone metastasis can be diagnosed using laboratory tests, radiographic examinations, CAT scans, MRI and biopsy. Bone metastasis treatment can include pain management, radiation, surgery and medical interventions.

Bone Metastases - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bone Metastases pipeline landscape is provided which includes the disease overview and Bone Metastases treatment guidelines. The assessment part of the report embraces, in depth Bone Metastases commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bone Metastases collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Bone Metastases.
• In the coming years, the Bone Metastases market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Bone Metastases R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Bone Metastases treatment market. Several potential therapies for Bone Metastases are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Bone Metastases market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Bone Metastases) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bone Metastases Emerging Drugs Chapters

This segment of the Bone Metastases report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bone Metastases Emerging Drugs

MW032: Mabwell (Shanghai) Bioscience Co., Ltd.MW032 is a Denosumab biosimilar being developed by Mabwell (Shanghai) Bioscience Co., Ltd. Denosumab is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NF?B ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. MW032 is currently in Phase III stage of development to treat Bone Metastases from Solid Tumors.

ALMB-0168: AlaMab TherapeuticsALMB-0168 is a first-inclass humanized monoclonal antibody agonist for hemichannel Cx43 membrane protein. Through the activation of Cx43 protein to release tumor-inhibiting cytokines, ALMB-0168 has shown to effectively inhibit osteosarcoma and bone metastasis in pre-clinical in vitro and in vivo animal studies. ALMB-0168 has received Orphan Disease Drug and Rare Pediatric Disease designations from the FDA for its use in osteosarcoma.

Bone Metastases: Therapeutic Assessment

This segment of the report provides insights about the different Bone Metastases drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bone Metastases

There are approx. 10+ key companies which are developing the therapies for Bone Metastases. The companies which have their Bone Metastases drug candidates in the most advanced stage, i.e. phase III include, Mabwell (Shanghai) Bioscience Co., Ltd.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Bone Metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bone Metastases: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bone Metastases therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bone Metastases drugs.

Bone Metastases Report Insights

• Bone Metastases Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bone Metastases Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bone Metastases drugs?
• How many Bone Metastases drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bone Metastases?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bone Metastases therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bone Metastases and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mabwell (Shanghai) Bioscience Co., Ltd.
• AlaMab Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Exelixis
• Shanghai JMT-Bio Inc.
• BiologicsMD
• Luye Pharma Group Ltd.
• QSAM Biosciences Inc.
• Serene, LLC
• Isotopen Technologien Munchens

Key Products

• MW032
• ALMB-0168
• QL1206
• Cabozantinib
• JMT103
• BMD 3151
• LY01011
• CycloSam
• Tin-117m
• ITM-41

This product will be delivered within 1-3 business days.